IL-31-Receptor‑α Antagonist Nemolizumab in Treatment‑Refractory Brachioradial Pruritus: A Case Report - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Nemolizumab, an IL-31 Receptor-α Antagonist, for Refractory Brachioradial Pruritus: A Case Report

  • By

  • Manuel P. Pereira

  • Eva M. Grekowitz

  • Martin Metz

  • November 20, 2026

Share

Clinical Report: Nemolizumab for Refractory Brachioradial Pruritus

Overview

In this case report, a 65-year-old woman with more than 4 years of treatment-refractory brachioradial pruritus (BRP) experienced a rapid reduction in itch after starting nemolizumab. Itch scores remained low during follow-up, and dermatology- and itch-related quality-of-life scores improved; the report adds a single case to the limited evidence for biologic treatment of BRP.

Background

BRP is a localized neuropathic pruritus that typically affects the dorsolateral forearms and may involve burning, stinging, or tingling, often with temporary relief from cold. Its proposed pathogenesis includes UV-related cutaneous nerve injury and degenerative cervical spine changes, and the condition can substantially impair quality of life. Management options described in the report include trigger avoidance, topical therapies, anticonvulsants, antidepressants, and opioid receptor modulators, with variable responses. The authors identify IL-31 as a therapeutic target of interest because of its role in neuroimmune itch mechanisms, while noting that options for refractory BRP remain limited.

Data Highlights

Measure or treatmentReported finding
Patient65-year-old woman with localized symptoms for more than 4 years
Prior treatmentTopical agents, antihistamines, and gabapentin up to 1200 mg/day did not provide relevant improvement; pregabalin and naltrexone were continued with intermittent but unsustained improvement
Nemolizumab regimen60 mg loading dose, followed by 30 mg every 4 weeks; pregabalin and naltrexone continued
Worst itch numerical rating scale (WI-NRS)Decreased from 7–9/10 to 3/10 within 10 days; subsequently most often 0–1/10
Quality of lifeBaseline DLQI and ItchyQoL indicated substantial impairment; both declined markedly after the first dose and subsequently stabilized

Key Findings

  • The patient reported bilateral arm pruritus, burning, and pain for more than 4 years, with sleep impairment and temporary relief from cold.
  • Examination showed diffuse erythema, mild lichenification, and excoriations; biopsy findings were compatible with chronic scratch lesions. Cervical spine imaging was not performed.
  • Earlier topical treatments, antihistamines, and gabapentin did not produce relevant improvement; pregabalin and naltrexone were associated with intermittent improvement but not sustained antipruritic efficacy.
  • After nemolizumab was initiated alongside established pregabalin and naltrexone, WI-NRS decreased from 7–9/10 to 3/10 within 10 days and was subsequently most often 0–1/10.
  • DLQI and ItchyQoL scores declined markedly after the first nemolizumab dose and then stabilized, according to the report.
  • The discussion cites one published dupilumab case with nearly complete itch improvement after 12 weeks and a multicenter nemolizumab case series that included one BRP case with a rapid but transient response; the authors note that evidence for biologic therapy in BRP remains limited.

Conclusion

Nemolizumab was associated with sustained low itch scores and marked quality-of-life improvement in this single reported case of refractory BRP. The authors characterize the evidence for biologic therapy in BRP as limited and call for further study.

Related Resources & Content

  1. European Dermatology Forum, European Guideline on Chronic Pruritus, 2025
  2. MDSpire News, Rapid Itch Relief Seen with Nemolizumab
  3. MDSpire News, FDA Approves for Nemolizumab to Treat Prurigo Nodularis
  4. Dermatology and Therapy, Nemolizumab Versus Dupilumab in the Treatment of Prurigo Nodularis: Systematic Literature Review and Network Meta-analysis
  5. MDSpire News — Phase 3 Data: Nemolizumab for Prurigo Nodularis Relief
  6. European Guideline on Chronic Pruritus: In cooperation with the European Dermatology Forum (EDF)
  7. Rapid Itch Relief Seen with Nemolizumab
  8. FDA Approves for Nemolizumab to Treat Prurigo Nodularis
  9. label

Original Source(s)

Related Content